A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Inclusion Criteria:

• Have a diagnosis of Type 2 diabetes mellitus (T2D) for at least 6 months beforescreening

• Have an HbA1c ≥7% and ≤10.5% at screening

• Management of T2D with diet and exercise alone or with either a stable dose ofmetformin or/and sodium-glucose cotransporter-2 (SGLT-2) inhibitors

• Body mass index (BMI) ≥23.0 kg/m^2 at screening

• A stable body weight within 3 months prior to screening (maximum 5% self-reportedbody weight gain and/or loss)

Exclusion Criteria:

• Have Type 1 diabetes (T1D), history of ketosis or hyperosmolar state/coma, or anyother types of diabetes except T2D

• Have had 1 or more episodes of Level 3 hypoglycemia or has hypoglycemia unawarenesswithin the 6 months prior to screening

• History or presence of proliferative diabetic retinopathy, diabetic macular edema,or non-proliferative diabetic retinopathy that requires acute treatment

• Evidence of clinically significant/active nephropathy or neuropathy (includingresting tachycardia, orthostatic hypotension, and diabetic diarrhea)

• Current treatment or treatment within 3 months of screening with any otheranti-hyperglycemic medication except metformin or SGLT-2 inhibitors

• Have obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) ordiagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin-4 receptordeficiency or Prader-Willi Syndrome)

• Have a known, clinically significant gastric emptying abnormality

• Have poorly controlled hypertension at screening, untreated renal artery stenosis,or evidence of labile blood pressure including symptomatic postural hypotension

• Have any of the following cardiovascular conditions within 3 months prior toscreening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transientischemic attack; Unstable angina; Hospitalization due to congestive heart failure